15 July
2024
Graft Polymer (UK)
Plc
("Graft Polymer" or the
"Company")
Director resignation and
launch of new corporate website and social media
profiles
Graft Polymer (UK) Plc (LON: GPL),
an innovative biopolymer drug delivery systems development company,
announces the resignation of Mr. Pavel Kobzev from its board of
directors with immediate effect. This follows the Company's recent
divestiture of its industrial plastics business unit, Graft Polymer
D.O.O., announced on 3 May 2024, and the successful completion of
its recent fundraise, details of which were announced on 3 July
2024.
Additionally, the Company is pleased
to announce the launch of its new corporate website and updated
LinkedIn and X (formerly Twitter) profiles. These platforms are
designed to reflect the Company's strategic focus on supporting
biopharmaceutical companies to enhance the bioavailability,
pharmacokinetics, and stability of their therapeutics.
Visit us online:
www.graftpolymer.co.uk
LinkedIn
X
(formerly Twitter)
Enquiries
Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive
Director, Email: anthonytennyson@graftpolymer.co.uk
Yifat Steuer, CFO and Executive
Director, Email: yifat@graftpolymer.co.uk
Allenby Capital (Broker)
Nick Naylor / Liz Kirchner / James
Reeve (Corporate Finance)
Guy McDougall
(Sales)
+44 (0) 20 3328
5656
About Graft Polymer (UK) Plc
Graft Polymer (UK) Plc (LON:GPL) is
an innovative developer of biopolymer drug delivery systems
dedicated to assisting biopharmaceutical companies in enhancing the
effectiveness of their therapeutics. Our proprietary patented
platform, a bioabsorbable self-nanoemulsifying drug delivery system
(SNEDDS), represents a cutting-edge solution in drug delivery
technology. By integrating active pharmaceutical ingredients (APIs)
into our novel, patented delivery systems, we enable clients to
improve the bioavailability, pharmacokinetics, and stability of
their therapeutics.
www.graftpolymer.co.uk
| LinkedIn
| X (formerly
Twitter)